About Us
Company Overview Executive Team Board of Directors Scientific Advisory Board Contact
Science & Pipeline
R&D Platform Pipeline Publications
Patients
Partners
Business Development Current Partners
Media
Press Release Media Report
Careers
Corporate Culture Job Opportunities
中文
中文
About Us
Company Overview Executive Team Board of Directors Scientific Advisory Board Contact
Science & Pipeline
R&D Platform Pipeline Publications
Patients
Partners
Business Development Current Partners
Media
Press Release Media Report
Careers
Corporate Culture Job Opportunities
Develop Differentiated Innovative Medicines
R&D Platform
Pipeline
AN2025 (buparlisib) AN0025 (palupiprant) AN4005 AN3025 AN1025 AN8025 AN6025
Publications

AN2025

28 2018-02
Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1
25 2017-01
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or static squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial


AN0025

17 2020-06
First-in- human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers
27 2019-09
A Phase 1b Study of E7046 (AN0025) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Rectal Cancer

AN3025

16 2022-02
Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity

AN1004

06 2022-12
A multicenter, single-arm, open-label Phase I study of AN1004 (Pelareorep) oncolytic virus plus paclitaxel in Chinese patients with Hormone receptor-positive and HER2-negative advanced/static breast cancer (REO 026-1)
13 2017-10
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with static breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
About Us
Company Overview Executive Team Board of Directors Scientific Advisory Board
Science & Pipeline
R&D Platform Pipeline
Patients
Partners
Business Development Current Partners
Media
Press Release Media Report
Careers
Corporate Culture Job Opportunities
Contact
Address:685 US Hwy 1, North Brunswick Township, NJ 08902, the United States Tel: +1 848 230 7430
Copyright © 2020 Hangzhou Adlai Nortye Biopharma Co., Ltd. All rights reserved Zhejiang ICP 15000014-1 Zhejiang Public Network Security 33011802000947 | Privacy Policy